Barry R. Keith

3.3k total citations · 3 hit papers
13 papers, 2.1k citations indexed

About

Barry R. Keith is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Barry R. Keith has authored 13 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 4 papers in Molecular Biology and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Barry R. Keith's work include HER2/EGFR in Cancer Research (5 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Biochemical and Molecular Research (3 papers). Barry R. Keith is often cited by papers focused on HER2/EGFR in Cancer Research (5 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Biochemical and Molecular Research (3 papers). Barry R. Keith collaborates with scholars based in United States and Germany. Barry R. Keith's co-authors include Robert J. Mullin, David W. Rusnak, Krystal J. Alligood, Tona M. Gilmer, Hong Ma, Neil L. Spector, Gary Owens, Wenle Xia, Doris M. Murray and Karen Affleck and has published in prestigious journals such as Cancer Research, Oncogene and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Barry R. Keith

13 papers receiving 2.1k citations

Hit Papers

Activity of the Dual Kinase Inhibitor Lapatinib (GW572016... 2001 2026 2009 2017 2006 2001 2002 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells
    2006 711 citations Gottfried E. Konecny, Mark D. Pegram et al. Cancer Research profile →
  2. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.
    2001 590 citations David W. Rusnak, Karen Lackey et al. PubMed profile →
  3. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
    2002 548 citations Wenle Xia, Robert J. Mullin et al. Oncogene profile →

Peers

Barry R. Keith
Lindy G. Durrant United Kingdom
Klaus Bosslet Germany
M. V. Pimm United Kingdom
Christopher Dean United Kingdom
Kevin J. Scanlon United States
Dagmar Hess Switzerland
Vanesa Gregorc Italy
Michael J. Mitten United States
R. K. Oldham United States
Kenneth Kolinsky United States
Lindy G. Durrant United Kingdom
Barry R. Keith
Citations per year, relative to Barry R. Keith Barry R. Keith (= 1×) peers Lindy G. Durrant

Countries citing papers authored by Barry R. Keith

Since Specialization
Citations

This map shows the geographic impact of Barry R. Keith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barry R. Keith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barry R. Keith more than expected).

Fields of papers citing papers by Barry R. Keith

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barry R. Keith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barry R. Keith. The network helps show where Barry R. Keith may publish in the future.

Co-authorship network of co-authors of Barry R. Keith

This figure shows the co-authorship network connecting the top 25 collaborators of Barry R. Keith. A scholar is included among the top collaborators of Barry R. Keith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barry R. Keith. Barry R. Keith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Konecny, Gottfried E., Mark D. Pegram, Natarajan Venkatesan, et al.. (2006). Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells. Cancer Research. 66(3). 1630–1639. 711 indexed citations breakdown →
2.
Mullin, Robert J., Doris M. Murray, James A. Onori, & Barry R. Keith. (2004). Xenograft response to combination therapy with the ErbB1-ErbB2 tyrosine kinase inhibitor GW572016.. 64. 882–882. 3 indexed citations
3.
Gaul, Micheal D., Yu Guo, Karen Affleck, et al.. (2003). Discovery and Biological Evaluation of Potent Dual ErbB-2/EGFR Tyrosine Kinase Inhibitors: 6-Thiazolylquinazolines. Bioorganic & Medicinal Chemistry Letters. 13(4). 637–640. 40 indexed citations
4.
Xia, Wenle, Robert J. Mullin, Barry R. Keith, et al.. (2002). Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene. 21(41). 6255–6263. 548 indexed citations breakdown →
5.
6.
7.
Mullin, Robert J., Barry R. Keith, Eric C. Bigham, et al.. (1992). In vivo antitumor activity and metabolism of a series of 5-deazaacyclotetrahydrofolate (5-DACTHF) analogues. Biochemical Pharmacology. 43(7). 1627–1634. 11 indexed citations
8.
Keith, Barry R., et al.. (1990). Effect of type 1 piliation on in vitro killing of Escherichia coli by mouse peritoneal macrophages. Infection and Immunity. 58(10). 3448–3454. 29 indexed citations
9.
Hanlon, Mary H., Robert Ferone, Robert J. Mullin, & Barry R. Keith. (1990). In vivo and in vitro metabolism of 5-deazaacyclotetrahydrofolate, an acyclic tetrahydrofolate analogue.. PubMed. 50(11). 3207–11. 14 indexed citations
10.
Keith, Barry R., et al.. (1989). In vivo efficacy of zidovudine (3'-azido-3'-deoxythymidine) in experimental gram-negative-bacterial infections. Antimicrobial Agents and Chemotherapy. 33(4). 479–483. 35 indexed citations
11.
Mullin, Robert J., Barry R. Keith, & David S. Duch. (1988). Distribution and Metabolism of Calcium Leucovorin in Normal and Tumor Tissue. Advances in experimental medicine and biology. 244. 25–38. 18 indexed citations
12.
Elwell, Lynn P., H.R. WILSON, Victoria B. Knick, & Barry R. Keith. (1986). In vitro and in vivo efficacy of the combination trimethoprim-sulfamethoxazole against clinical isolates of methicillin-resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy. 29(6). 1092–1094. 39 indexed citations
13.
Keith, Barry R., Lisa M. Maurer, Patricia A. Spears, & Paul E. Orndorff. (1986). Receptor-binding function of type 1 pili effects bladder colonization by a clinical isolate of Escherichia coli. Infection and Immunity. 53(3). 693–696. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lindy G. Durrant Breakdown of academic impact, for papers by Klaus Bosslet Breakdown of academic impact, for papers by M. V. Pimm Breakdown of academic impact, for papers by Christopher Dean Breakdown of academic impact, for papers by Kevin J. Scanlon Breakdown of academic impact, for papers by Dagmar Hess Breakdown of academic impact, for papers by Vanesa Gregorc Breakdown of academic impact, for papers by Michael J. Mitten Breakdown of academic impact, for papers by R. K. Oldham Breakdown of academic impact, for papers by Kenneth Kolinsky
Rankless by CCL
2026